NSE: POLYMED · 27 October 2026
- Poly Medicure Ltd. shares traded higher today, rising 1.68% to close at ₹1,467.80 compared to its previous close of ₹1,443.50.
- The company announced a virtual one-on-one meeting scheduled with Dam Capital on 25th September 2026. The filing noted that the interaction was arranged on shorter notice following a confirmation received from the participant.
- Trading volume was 0.26 times the 20-day average daily volume.
Why is Poly Medicure share price rising on 27 October 2026?
Poly Medicure Ltd. shares traded higher today, rising 1.68% to close at ₹1,467.80 compared to its previous close of ₹1,443.50.
The broader market showed subdued momentum, with the Nifty edging down by 0.02%. Meanwhile, the relevant sector benchmark, Nifty Pharma, outperformed with a gain of 2.06%. Poly Medicure's upward movement occurred against the backdrop of recent weakness, having posted a 5-day return of -5.35% and a 20-day return of -14.88%.
On the company front, recent developments include ongoing investor and analyst interactions, such as one-on-one meetings hosted during late September 2026 with institutions like Avendus Spark and Dam Capital. These engagements provide context on institutional outreach but do not represent a direct causal trigger for today's price action.
26,637 shares traded by 27 October 2026 · 02:55 PM IST. This compares with a 20-day average daily volume of 1.01 lakh shares (0.26 times). The five-day average daily volume was 1.16 lakh shares. Separately, the NSE report for 26 October 2026 showed 21,971 shares delivered, representing 50.60% of that day’s traded volume. The same report recorded 9,302 trades.
No single confirmed company announcement or catalyst directly explains today's 1.68% advance. The move appears consistent with a technical rebound following recent declines, supported by broader sector momentum in healthcare.
Latest Company Developments
The company announced a virtual one-on-one meeting scheduled with Dam Capital on 25th September 2026. The filing noted that the interaction was arranged on shorter notice following a confirmation received from the participant.
Reflects continued institutional outreach to discuss business developments within regulatory guidelines.
Poly Medicure submitted the scrutinizer's report and voting results for its 31st Annual General Meeting held on 5th September 2026. All ordinary and special resolutions, including the adoption of financial statements, the declaration of dividend, and the re-appointment of directors, were duly passed by the shareholders.
Confirms shareholder approval for key corporate actions and governance items for the financial year.
Poly Medicure Limited has informed the Exchange that Record date for the purpose of Dividend is 29-Aug-2026.
Investor Call Scheedule to be held on 20th August, 2026 is Cancelled.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 9.77% on 30 September 2026. This compares with 9.61% on 30 June 2026, a change of +0.16 percentage points.
The filing reported 23 MF/UTI holders.
What to Watch Next
- Execution progress on recent acquisitions and international expansion plans
- Upcoming quarterly financial results and margin performance
- Delivery volume trends relative to the 20-day average volume of 0.26x
- Broader sector sentiment across Nifty Pharma and healthcare stocks
More Poly Medicure news and dated analysis →
Frequently Asked Questions
What is the latest Poly Medicure company news?
The company announced a virtual one-on-one meeting scheduled with Dam Capital on 25th September 2026. The filing noted that the interaction was arranged on shorter notice following a confirmation received from the participant.
How strong was Poly Medicure’s trading volume?
26,637 shares traded, 0.26 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 · 02:55 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.